SEC 13F Intelligence

Managers / Q2 2021 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$167M
Q2 2021
Positions
62
Filings on Record
39
2019–present window
Filed
Aug 10, 2021
original filing

Summary

Birchview Capital, LP reported $167M in U.S.-listed holdings across 62 positions for Q2 2021.

The portfolio is heavily concentrated: BMY alone accounts for 31.8% of reported value.

Compared with Q1 2021, the fund opened 9 new positions and exited 1.

Portfolio Metrics

Turnover
+8.2%
vs prior filed quarter
Top-10 Concentration
+72.2%
share of reported value
Largest Position
+31.8%
Bristol Myers Squibb
New / Exited
9 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 72.9%Other: 27.1%
  • Common Stock · 72.9% · $122M
  • Other · 27.1% · $45M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
PROTHENA CORP PLCNEW+30.2K30.2K+$2M$2M
TURNING POINT THERAPEUTICS INCNEW+8.0K8.0K+$624,000$624,000
ZNTLZENTALIS PHARMACEUTICALS INCNEW+8.0K8.0K+$426,000$426,000
AKBAAKEBIA THERAPEUTICS INCNEW+100.0K100.0K+$379,000$379,000
SIENTRA INCNEW+40.0K40.0K+$318,000$318,000
ELUTAZIYO BIOLOGICS INCNEW+30.0K30.0K+$288,000$288,000
KINIKSA PHARMACEUTICALS LTDNEW+20.0K20.0K+$279,000$279,000
CYTKCYTOKINETICS INCNEW+10.0K10.0K+$198,000$198,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2021

62 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BMYBRISTOL-MYERS SQUIBB COhistory →COM31.82%$53M796.1K
2ACCELERATE DIAGNOSTICS INCCOM10.74%$18M2.23M
3BIODESIX INCCOM8.73%$15M1.10M
4NBIXNEUROCRINE BIOSCIENCES INChistory →COM4.67%$8M80.2K
5QUIDEL CORPCOM4.57%$8M59.7K
6ACADACADIA PHARMACEUTICALS INChistory →COM2.91%$5M199.4K
7BIIBBIOGEN INChistory →COM2.51%$4M12.1K
8BDQMALBIREO PHARMA INChistory →COM2.34%$4M111.0K
9FHTXFOGHORN THERAPEUTICS INChistory →COM2.01%$3M314.1K
10UTHRUNITED THERAPEUTICS CORPhistory →COM1.93%$3M18.0K
11KARYOPHARM THERAPEUTICS INCCOM1.42%$2M230.0K
12BLUEBIRD BIO INCCOM1.42%$2M74.0K
13XLRNACCELERON PHARMA INChistory →COM1.40%$2M18.7K
14MASIMO CORPCOM1.16%$2M8.0K
15ANGION BIOMEDICA CORPCOM1.16%$2M60.6K
16VNDAVANDA PHARMACEUTICALS INChistory →COM1.03%$2M80.0K
17HROWHARROW HEALTH INChistory →COM1.00%$2M180.0K
18PROTHENA CORP PLCSHS0.93%$2M30.2K
19ARENA PHARMACEUTICALS INCCOM0.90%$2M22.0K
20CONTINENTAL RESOURCES INCCOM0.88%$1M38.6K
21AMARIN CORP PLCSPONS ADR NEW0.79%$1M300.0K
22IMMUNOGEN INCCOM0.75%$1M190.0K
23NEKTAR THERAPEUTICSCOM0.74%$1M72.0K
24ALKSALKERMES PLCSHS0.73%$1M50.0K
25CGEMCULLINAN ONCOLOGY INCCOM0.70%$1M45.1K
26ARVNARVINAS INCCOM0.69%$1M15.0K
27EQUITRANS MIDSTREAM CORPORATIOCOM0.68%$1M133.1K
28CORTCORCEPT THERAPEUTICS INCCOM0.66%$1M50.0K
29OVVOVINTIV INCCOM0.64%$1M34.2K
30SOLENO THERAPEUTICS INCCOM0.60%$1M876.9K
31BIOHAVEN PHARMACEUTICAL HOLDING CO LTDCOM0.58%$971,00010.0K
32PROGENITY INCCOM0.58%$964,000270.0K
33KALVISTA PHARMACEUTICALS INCCOM0.57%$958,00040.0K
34PGNYPROGYNY INCCOM0.53%$885,00015.0K
35CONTRAFECT CORPCOM0.53%$880,000200.0K
36G1 THERAPEUTICS INCCOM0.53%$878,00040.0K
37TRANSLATE BIO INCCOM0.49%$826,00030.0K
38INARI MEDICAL INCCOM0.39%$653,0007.0K
39TURNING POINT THERAPEUTICS INCCOM0.37%$624,0008.0K
40PIONEER NATURAL RESOURCES COCOM0.37%$618,0003.8K
41TGTXTG THERAPEUTICS INCCOM0.35%$582,00015.0K
42ASPIRA WOMENS HEALTH INCCOM0.35%$579,000103.1K
43APELLIS PHARMACEUTICALS INCCOM0.30%$506,0008.0K
44STOKSTOKE THERAPEUTICS INCCOM0.30%$505,00015.0K
45PTGXPROTAGONIST THERAPEUTICS INCCOM0.27%$449,00010.0K
46ZNTLZENTALIS PHARMACEUTICALS INCCOM0.25%$426,0008.0K
47XNCRXENCOR INCCOM0.25%$424,00012.3K
48LSFLAIRD SUPERFOOD INCCOM0.25%$418,00014.0K
49CHEMOCENTRYX INCCOM0.24%$402,00030.0K
50AKBAAKEBIA THERAPEUTICS INCCOM0.23%$379,000100.0K
51DICERNA PHARMACEUTICALS INCCOM0.22%$373,00010.0K
52AMICUS THERAPEUTICS INCCOM0.22%$366,00038.0K
53SIENTRA INCCOM0.19%$318,00040.0K
54BCRXBIOCRYST PHARMACEUTICALS INCCOM0.19%$316,00020.0K
55ELUTAZIYO BIOLOGICS INCCOM0.17%$288,00030.0K
56KINIKSA PHARMACEUTICALS LTDCOM0.17%$279,00020.0K
57ARQTARCUTIS BIOTHERAPEUTICS INCCOM0.15%$246,0009.0K
58INFLARX NVCOM0.12%$208,00070.0K
59CYTKCYTOKINETICS INCCOM0.12%$198,00010.0K
60HOOKIPA PHARMA INCCOM0.11%$183,00020.0K
61THERAPEUTICSMD INCCOM0.07%$119,000100.0K
62CONCERT PHARMACEUTICALS INCCOM0.05%$84,00020.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.